Q-omics provides the consensus-scored OR9H1P profile across patient tissues and cancer cell-line models. OR9H1P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OR9H1P is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, OR9H1P RNA expression shows 8,061 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, COAD, and TGCT as cancer lineages where OR9H1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR9H1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR9H1P survival associations across molecular data types. OR9H1P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR9H1P RNA expression–survival associations across cancer types. High OR9H1P expression shows unfavorable associations in ACC, BLCA, BRCA, LIHC and PCPG, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for OR9H1P RNA expression.
This table summarizes OR9H1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR9H1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR9H1P shows lower tumor expression in COAD, THCA and STAD and higher tumor expression in PRAD. The COAD box plot shows higher OR9H1P RNA expression in normal versus tumor tissue (log2 FC = −0.042, t-test p = .002).
This table shows molecular features associated with OR9H1P in patient tissues and cancer cell lines. In patient samples, OR9H1P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
